Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice

Biochem Biophys Res Commun. 2016 Apr 29;473(2):530-6. doi: 10.1016/j.bbrc.2016.03.107. Epub 2016 Mar 23.

Abstract

Recent reports suggest that gut microbiota can be a major determinant of dyslipidemia and non-alcoholic fatty liver disease (NAFLD) and its modulation by treating probiotics is a valid strategy to exert a protective effect. In this study, high-fat diet (HFD)-fed mice were orally administrated with Lactobacillus rhamnosus GG (LGG) for 13 weeks. Significant reductions in the weights of the liver, mesenteric and subcutaneous adipose tissues were observed in LGG-treated HFD-fed mice compared to LGG-non-treated controls. The serum levels of triglyceride and cholesterol were also significantly reduced in LGG-treated mice. Gut microbial composition analysis showed that shifts in the diversity of dominant gut bacteria were caused by HFD and restored by LGG treatment. A remarkable decrease of hepatic fat content was also observed in LGG-treated mice, accompanied by downregulated expressions of lipogenic and pro-inflammatory genes in the liver. LGG-treated mice had lower expression levels of genes involved in cholesterol synthesis, but conversely, higher expression levels of cholesterol efflux-related genes compared to LGG-non-treated controls. The cholesterol-lowering effect of LGG was also found to be mediated by suppression of FXR and FGF15 signaling, resulting in the upregulation of hepatic CYP7A1. Our findings confirm a therapeutic potential of probiotics for ameliorating dyslipidemia and NAFLD.

Keywords: Cholesterol; Dyslipidemia; Gut microbiota; Lactobacillus rhamnosus GG; Non-alcoholic fatty liver disease (NAFLD).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cholesterol / metabolism*
  • Diet, High-Fat / adverse effects
  • Dyslipidemias / metabolism
  • Dyslipidemias / pathology
  • Dyslipidemias / therapy*
  • Gastrointestinal Microbiome
  • Lactobacillus rhamnosus* / physiology
  • Lipid Metabolism
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Mice, Inbred C57BL
  • Mice, Obese
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Non-alcoholic Fatty Liver Disease / pathology
  • Non-alcoholic Fatty Liver Disease / therapy*
  • Probiotics / therapeutic use*

Substances

  • Cholesterol